Abstract
Blood and serum N-glycans can be used as markers for cancer diagnosis, as alterations in protein glycosylation are associated with cancer pathogenesis and progression. We aimed to develop a platform for breast cancer (BrC) diagnosis based on serum N-glycan profiles using MALDI-TOF mass spectroscopy. Serum N-glycans from BrC patients and healthy volunteers were evaluated using NosQuest’s software “NosIDsys.” BrC-associated “NosID” N-glycan biomarkers were selected based on abundance and NosIDsys analysis, and their diagnostic potential was determined using NosIDsys and receiver operating characteristic curves. Results showed an efficient pattern recognition of invasive ductal carcinoma patients, with very high diagnostic performance [area under the curve (AUC): 0.93 and 95% confidence interval (CI): 0.917–0.947]. We achieved effective stage-specific differentiation of BrC patients from healthy controls with 82.3% specificity, 84.1% sensitivity, and 82.8% accuracy for stage 1 BrC and recognized hormone receptor-2 and lymph node invasion subtypes based on N-glycan profiles. Our novel technique supplements conventional diagnostic strategies for BrC detection and can be developed as an independent platform for BrC screening.
Highlights
Detection of breast cancer (BrC) is associated with more treatment options, better surgical conditions, increased survival, and improved quality of life
While various criteria exist for classification of BrC, it is most commonly classified into non-invasive BrC or invasive ductal carcinoma (IDC; stages 1–4)
We identified 24 NosID glycan biomarkers for differentiating healthy volunteers from N (-) and N (+) BrC subtypes
Summary
Detection of breast cancer (BrC) is associated with more treatment options, better surgical conditions, increased survival, and improved quality of life. While various criteria exist for classification of BrC, it is most commonly classified into non-invasive BrC (stage 0) or invasive ductal carcinoma (IDC; stages 1–4). The presence of hormone receptors (HR) in invasive BrC is a prognostic factor and the most powerful prognostic indicator of hormone suppression. N-glycomics in breast cancer diagnosis mentioned above are within the manuscript and its Supporting Information files
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
